Name | Fradafiban |
Synonyms | BIBU-52 Fradafiban 3-Pyrrolidineacetic acid, 5-[[[4'-(aminoiminomethyl)[1,1'-biphenyl]-4-yl]oxy]methyl]-2-oxo-, (3S,5S)- |
CAS | 148396-36-5 |
Molecular Formula | C20H21N3O4 |
Molar Mass | 367.403 |
Density | 1.38±0.1 g/cm3(Predicted) |
pKa | 4.29±0.10(Predicted) |
In vitro study | Fradafiban is a nonpeptide mimetic of the arginine-glycine-aspartic acid recognition sequence. Fradafiban binds with high affinity and selectivity to the human platelet GP IIb/IIIa complex and potently inhibits human platelet aggregation in vitro. Fradafiban reversibly binds to the human platelet GP IIb/IIIa complex with a K d value of 148 nM. |
In vivo study | Fradafiban has only very limited oral activity probably due to its high polarity and thus poor absorption after oral ingestion. |
biological activity | Fradafiban is a non-peptide platelet glycoprotein IIb/IIIa complex antagonist, it binds to the human platelet GP IIb/IIIa complex with a Kd value of 148 nM. |
Target | Kd: 148 nM (human platelet GP IIb/IIIa complex) |